JPWO2023004282A5 - - Google Patents

Info

Publication number
JPWO2023004282A5
JPWO2023004282A5 JP2024503420A JP2024503420A JPWO2023004282A5 JP WO2023004282 A5 JPWO2023004282 A5 JP WO2023004282A5 JP 2024503420 A JP2024503420 A JP 2024503420A JP 2024503420 A JP2024503420 A JP 2024503420A JP WO2023004282 A5 JPWO2023004282 A5 JP WO2023004282A5
Authority
JP
Japan
Prior art keywords
receptor agonist
amino acid
targeting moiety
monomer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528665A (ja
JP2024528665A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073832 external-priority patent/WO2023004282A2/en
Publication of JP2024528665A publication Critical patent/JP2024528665A/ja
Publication of JP2024528665A5 publication Critical patent/JP2024528665A5/ja
Publication of JPWO2023004282A5 publication Critical patent/JPWO2023004282A5/ja
Pending legal-status Critical Current

Links

JP2024503420A 2021-07-19 2022-07-18 Ｉｌ１２受容体アゴニスト及びその使用方法 Pending JP2024528665A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163223534P 2021-07-19 2021-07-19
US63/223,534 2021-07-19
US202163233084P 2021-08-13 2021-08-13
US63/233,084 2021-08-13
US202163281580P 2021-11-19 2021-11-19
US63/281,580 2021-11-19
US202263337038P 2022-04-29 2022-04-29
US63/337,038 2022-04-29
PCT/US2022/073832 WO2023004282A2 (en) 2021-07-19 2022-07-18 Il12 receptor agonists and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024528665A JP2024528665A (ja) 2024-07-30
JP2024528665A5 JP2024528665A5 (https=) 2025-07-28
JPWO2023004282A5 true JPWO2023004282A5 (https=) 2025-07-28

Family

ID=82846584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503420A Pending JP2024528665A (ja) 2021-07-19 2022-07-18 Ｉｌ１２受容体アゴニスト及びその使用方法

Country Status (10)

Country Link
US (2) US12522638B2 (https=)
EP (1) EP4373851A2 (https=)
JP (1) JP2024528665A (https=)
KR (1) KR20240035845A (https=)
AU (1) AU2022314734A1 (https=)
CA (1) CA3226924A1 (https=)
IL (1) IL310221A (https=)
MX (1) MX2024000882A (https=)
TW (1) TW202321282A (https=)
WO (1) WO2023004282A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
WO2023242769A1 (en) * 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
AU2024309243A1 (en) * 2023-06-27 2026-01-29 Lyell Immunopharma, Inc. Il-12 stability variants
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
WO2025119304A1 (en) * 2023-12-07 2025-06-12 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric proteins against il-12 receptor
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9824437D0 (en) 1998-11-06 1999-01-06 Ylo Herttuala Seppo Gene therapy
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005049094A1 (en) 2003-11-13 2005-06-02 Advantagene, Inc. A mixed complementary viral vector for gene therapy
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2012094623A2 (en) 2011-01-07 2012-07-12 Abbott Laboratories Anti-il-12/il-23 antibodies and uses thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2925785A4 (en) 2012-11-28 2016-11-16 Zymeworks Inc MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US20170216387A1 (en) 2014-08-01 2017-08-03 Illycaffe' S.P.A. Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
PL3368572T3 (pl) 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
SG11201802912PA (en) * 2015-10-10 2018-05-30 Intrexon Corp Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017125815A2 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
AU2017241776B2 (en) 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
MA45779A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Polypeptides immunomdulateurs et compositions et procédés associés
MX386014B (es) 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
MY203971A (en) 2016-10-13 2024-07-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
US20190367611A1 (en) 2017-02-01 2019-12-05 CentryMed Pharmaceutical Inc. Monomeric human igg1 fc and bispecific antibodies
SG11201912240QA (en) 2017-06-28 2020-01-30 Regeneron Pharma Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
CA3100005A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019333047A1 (en) 2018-08-30 2020-12-03 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EP3766512A1 (en) 2019-07-16 2021-01-20 Universität Zürich Fc-modified il-12 for local cns delivery
MX2022000991A (es) 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
US20220356221A1 (en) 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
JP7773991B2 (ja) 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法
AU2021248919A1 (en) 2020-04-01 2022-10-13 Xilio Development, Inc. Masked IL-12 cytokines and their cleavage products
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses
WO2022155263A2 (en) 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
US20240228586A1 (en) 2021-05-07 2024-07-11 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents

Similar Documents

Publication Publication Date Title
JP7313398B2 (ja) 腫瘍細胞の枯渇を亢進するための薬剤の組み合わせ
Hornig et al. Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy
CN107847587B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
Karches et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy
Müller et al. A novel antibody–4-1BBL fusion protein for targeted costimulation in cancer immunotherapy
JP2022500419A (ja) 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
JP7489468B2 (ja) 二重特異性融合タンパク質及びその応用
CA2416572C (en) Bispecific antibody for target cell-specific stimulation of the apo-1 cell surface receptor
JP2021528048A (ja) Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用
JP2020520665A5 (https=)
Peipp et al. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
CN105330750A (zh) 一种快速中止car-t细胞杀伤作用的分子刹车及其用途
CN108463245A (zh) 具有修饰的j链的结合分子
EP2646465B1 (en) Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
CN103536917B (zh) 干扰素在治疗肿瘤中的用途及相关的产品和方法
TW202144426A (zh) 四價雙特異性抗體、其製備方法和用途
JPWO2023004282A5 (https=)
EP2441776A1 (en) Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
WO2023104214A1 (zh) 包含lrrc15抗原结合结构域的多特异性t细胞接合剂
Taheri et al. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell
WO2024078479A1 (zh) 一种异源二聚体融合蛋白及其应用
JPWO2019147670A5 (https=)
Zhu et al. Highlights of antibody engineering and therapeutics 2019 in San Diego, USA: bispecific antibody design and clinical applications
CN118974258A (zh) 抗fap-alpha的人源抗体
US20250339527A1 (en) Bcma-targeted car-t cell therapy for multiple myeloma